Subgroup baseline analyses of overall survival.
ONCOLOGY
5-FU 5-fluorouracil, BEV bevacizumab, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor, FOLFIRI 5-FU, leucovorin, and irinotecan, FP fluoropyrimidine, FTD/TPI trifluridine/tipiracil, HR hazard ratio, IRI irinotecan, As for patient characteristics according to the intent-to-use 5-FU or S-1, there was a difference in 